SCHEMBL1579968

SCHEMBL1579968

NCCC(=O)N1CCC[N]CC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.45
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
TDP1 Q9NUW8 3/20 0.39
NPC1 O15118 3/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
SIGMAR1 Q99720 1/20 0.38
HPGD P15428 3/20 0.36
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
CYP3A4 P08684 1/20 0.36
RAB9A P51151 2/20 0.36
NAAA Q02083 1/20 0.35
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1578940 0.92 SIGMAR1 (0.41) ATMALDH1A1SMN1; SMN2L3MBTL1TDP1
SCHEMBL1580336 0.89 ATM (0.52) ATMALDH1A1SMN1; SMN2L3MBTL1TDP1
SCHEMBL1579948 0.88 ATM (0.50) ATMALDH1A1SMN1; SMN2L3MBTL1TDP1
SCHEMBL2682148 0.82 ATM (0.65) ATMALDH1A1SMN1; SMN2L3MBTL1TDP1
SCHEMBL8557452 0.81 L3MBTL1 (0.52) ATMALDH1A1SMN1; SMN2L3MBTL1TDP1
SCHEMBL1578576 0.81 ATM (0.48) ATMALDH1A1SMN1; SMN2L3MBTL1TDP1
SCHEMBL2832300 0.80 ATM (0.62) ATMALDH1A1SMN1; SMN2L3MBTL1TDP1
SCHEMBL6694116 0.80 ATM (0.62) ATMALDH1A1SMN1; SMN2L3MBTL1TDP1
SCHEMBL15224112 0.80 ATM (0.62) ATMALDH1A1SMN1; SMN2L3MBTL1TDP1
Hydrochloric Acid SCHEMBL856723 0.80 ATM (0.62) ATMALDH1A1SMN1; SMN2L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150051185-A1 Chemical Compounds 251 ASTRAZENECA AB (SE) 2015-02-19 US claimed
JP-2011526616-A 2011-10-13 JP claimed
US-20110218182-A1 CHEMICAL COMPOUNDS 251 ASTRAZENECA AB (SE) 2011-09-08 US claimed
EP-2310010-A2 CHEMICAL COMPOUNDS 251 AstraZeneca AB (SE) 2011-04-20 EP claimed
WO-2010001169-A2 CHEMICAL COMPOUNDS 251 ASTRAZENECA AB (SE) 2010-01-07 WO claimed
US-20150051185-A1 Chemical Compounds 251 ASTRAZENECA AB (SE) 2015-02-19 US disclosed
US-8901307-B2 Chemical compounds 251 ASTRAZENECA AB (SE) 2014-12-02 US disclosed
US-20110218182-A1 CHEMICAL COMPOUNDS 251 ASTRAZENECA AB (SE) 2011-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218182-A1 CHEMICAL COMPOUNDS 251 PIM1, PIM3, PIM2 ATM 710/4885ALDH1A1 498/4885SMN1; SMN2 3689/4885
US-20150051185-A1 Chemical Compounds 251 PIM1, PIM3, PIM2 ATM 649/4885ALDH1A1 683/4885SMN1; SMN2 4014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.